Novavax Inc is primarily active within the biotechnology and pharmaceutical industries.

The main competitors of Novavax Inc in the market are companies like Moderna, Pfizer, and Johnson & Johnson.

The business model of Novavax Inc revolves around developing innovative vaccines to address infectious diseases. Novavax is a biotechnology company that focuses on the discovery, development, and commercialization of vaccines for various viral infections. With a particular focus on respiratory diseases, including influenza and respiratory syncytial virus (RSV), Novavax utilizes cutting-edge technologies to create vaccines that stimulate protective immune responses. The company's approach includes the use of recombinant nanoparticle vaccine technology, which enables the production of vaccine antigens that closely mimic targeted viruses. Novavax strives to provide advanced vaccine solutions to combat prevalent and emerging infectious diseases worldwide.

Novavax Inc. is a leading biotechnology company focused on the development of innovative vaccines. Founded in 1987, Novavax has a rich history of scientific excellence and groundbreaking research. The company is committed to addressing urgent global health challenges and has made significant advancements in the field of vaccine development. Novavax has pioneered the use of recombinant nanoparticle vaccine technology and has successfully produced vaccine candidates for a range of infectious diseases, including respiratory syncytial virus (RSV), influenza, and COVID-19. With its strong research capabilities and dedicated team, Novavax continues to strive for transformative solutions in public health through its pioneering vaccine technologies.

Novavax Inc has achieved several significant milestones. One of the key achievements includes the development of a proprietary recombinant nanoparticle vaccine technology platform called Matrix-M. This innovative platform has facilitated the creation of multiple vaccine candidates targeting viral diseases. Novavax Inc has also successfully conducted clinical trials and achieved positive results for various vaccines, including those targeting respiratory syncytial virus (RSV) and influenza. Furthermore, the company has collaborated with renowned organizations, such as the Coalition for Epidemic Preparedness Innovations (CEPI) and the Bill & Melinda Gates Foundation, demonstrating its recognition and partnerships within the industry.

Novavax Inc is primarily present in multiple countries and regions. The company has a global presence and operates in various key markets. Some of the primary countries and regions where Novavax Inc is actively engaged include the United States, United Kingdom, Canada, Europe, and Australia. With its innovative and cutting-edge approach to vaccine development, Novavax Inc aims to offer its healthcare solutions to a wide range of international markets. The company's commitment to expanding its presence ensures that its groundbreaking medical technologies reach people across different countries and regions, fostering better health outcomes worldwide.

Novavax Inc represents values of innovation, dedication, and collaboration in the biotechnology industry. With a corporate philosophy focused on developing novel vaccines to prevent infectious diseases, Novavax aims to improve global health outcomes. Their commitment to scientific excellence and rigorous research enables them to address evolving public health challenges. Novavax Inc strives to make a positive impact by developing safe and effective vaccines, leveraging their technological expertise and diverse partnerships. Through their tireless efforts, Novavax Inc aims to provide innovative solutions to protect communities worldwide, solidifying their position as a leading biotech company.

Analysts currently set an average price target of 13,15 USD for the Novavax stock (median: 11,22 USD), implying +68,0 % versus the latest price. The consensus is based on 15 analyst ratings.

Novavax Analyytikkojen kursstavoitteet 2026

15 analysts currently rate the Novavax stock: 10 recommend buying, 2 holding and 3 selling. For 2026, analysts expect Novavax to generate revenue of 409,97 M USD and earnings per share of −0,42 USD.

Novavax Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Novavax share trades at 6,87 EUR (7,82 USD).

The Novavax share (NVAX) is listed on 8 stock exchanges, including: NASDAQ (NVAX), XETRA (NVV1.F), Frankfurt (NVV1.F), München (NVV1.MU), Düsseldorf (NVV1.DU), Hamburg (NVV1.HM), London (0A3S.L), SIX (Zürich) (NVV1.SW).

Novavax Inc. is a biopharmaceutical company specializing in the development of innovative vaccines and treatments for a variety of infectious diseases. The company was founded in 1987 and is headquartered in Gaithersburg, Maryland, USA.

odotettu liikevaihto Novavax on 409,97 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Novavax on −71,99 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Novavax:n hinta-voitto-suhde (P/E) on tällä hetkellä −18,82. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Novavax-osakkeen arvostusta.

Novavax:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,30. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Novavax-osakkeen arvostuskennuslukuna.

Novavax:n Eulpool-laatuscore on 5/10.

Novavax:n ISIN on US6700024010. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Novavax:n WKN on A2PKMZ. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Novavax:n ticker on NVAX. Tämä pörssinoteeraus käytetään Novavax-osakkeiden kauppaan pörssissä.

Novavax maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Novavax kuuluu sektoriin 'Terveydenhuolto'.

Novavax:n osingot jaetaan valuutassa USD.